NCT00267865 - Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2006

Primary Completion Date

September 18, 2019

Study Completion Date

September 19, 2019

Conditions

AIDS-Related-Primary Central Nervous System Lymphoma

Interventions

DRUG

Methotrexate

6000 mg/m\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.

DRUG

Rituximab

375 mg/m\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate

DRUG

Leucovorin

Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH